Kenvue Stock Plummets 9% Amid Tylenol-Autism Controversy

Kenvue Inc. shares tumbled 9.35% in Thursday trading following reports linking Health Secretary RFK Jr. to potential concerns about Tylenol's association with autism risks. The consumer health giant faces mounting pressure as analysts slash price targets amid regulatory uncertainty.

The selloff accelerated after Wall Street Journal reports suggested prenatal Tylenol use might be tied to autism spectrum disorders. Market capitalization now stands at $39.42 billion, with year-to-date losses deepening to 1.06%.

Strategic review proceedings continue as investors weigh potential litigation risks and reputational damage to Kenvue's flagship analgesic brand. The abrupt decline underscores market sensitivity to health-related controversies in the consumer staples sector.